Back to today’s briefing

Story perspectives

Verzenio Cuts Breast Cancer Death Risk by 15.8%

10/18/2025

33 8

Summary

Story summary

Eli Lilly and Company's Verzenio, added to endocrine therapy, reduced death risk by 15.8% in HR-positive, HER2-negative early breast cancer (MonarchE trial).
This marks the first notable breast cancer overall survival improvement in more than 20 years.
Median follow-up was 6.3 years, with no new safety concerns reported.
Analysts expect Verzenio sales could reach $8 billion by 2030.

1 of 1

Story summary

Eli Lilly and Company's Verzenio, added to endocrine therapy, reduced death risk by 15.8% in HR-positive, HER2-negative early breast cancer (MonarchE trial).
This marks the first notable breast cancer overall survival improvement in more than 20 years.
Median follow-up was 6.3 years, with no new safety concerns reported.
Analysts expect Verzenio sales could reach $8 billion by 2030.